v3.26.1
Note 10 - Stock-based Compensation - Schedule of Stock Options Outstanding (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Outstanding stock options (in shares) 45,834  
Outstanding stock options, weighted average exercise price (in dollars per share) $ 354.62  
Outstanding stock options, remaining contractual term (Year) 8 years 7 months 6 days [1] 6 years 7 months 6 days
Outstanding stock options, intrinsic value [2] $ 2 [1] $ 0
Granted, options (in shares) [3] 68,084  
Granted, options, weighted average exercise price (in dollars per share) [3] $ 9.27  
Exercised, options (in shares) 0  
Exercised, options, weighted average exercise price (in dollars per share) $ 0  
Forfeited, options (in shares) (3,076)  
Forfeited, options, weighted average exercise price (in dollars per share) $ 1,326.36  
Outstanding stock options (in shares) 110,842 [1] 45,834
Outstanding stock options, weighted average exercise price (in dollars per share) $ 115.53 [1] $ 354.62
Vested and exercisable stock options at June 30, 2026 (in shares) 33,576  
Vested and exercisable stock options, weighted average exercise price (in dollars per share) $ 355.18  
Vested and exercisable stock options, remaining contractual term (Year) 6 years 6 months  
Vested and exercisable stock options at June 30, 2026 [2] $ 0  
[1] The outstanding stock options presented in the table above are inclusive of 1,816 stock options granted outside the PAVmed 2014 Equity Plan, as of March 31, 2026 and December 31, 2025.
[2] The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of March 31, 2026 and December 31, 2025 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.
[3] Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.